EDCTP to grant 21.9 million euros to PAMAfrica research consortium
Category: #health  By Pankaj Singh  Date: 2020-03-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

EDCTP to grant 21.9 million euros to PAMAfrica research consortium

 

  • EDCTP has granted the PAMAfrica research consortium 21.9 million euros over a 5 year period while the other International research partners like MMV, Novartis, and others would contribute 22 million euros.
  • Project would include development of first new malaria treatment for infants under 5 kg, new combinations to treat drug resistant malaria, and a fast acting medicine for treatment of severe malaria.

In a recent news, the European and Developing Countries Clinical Trials Partnership, EDCTP, presented a grant of 21.9 million euros to the PAMAfrica research consortium led by Medicines for Malaria Venture (MMV). The consortium is expected to aid the development of new medications for malaria across the vulnerable population that includes newborn infants, and patients with severe malaria drug-resistant infections. Moreover, the International research partnership would contribute a significant amount of 22 million euros making the total investment near to 44 million euros. 

It has been reported that the grant, over the period of five years, would support the development of a portfolio of projects carried out under the banner of PAMAfrica research consortium which is likely to conduct three trials to build clinical capacity and educate scientists across Africa.

As per official sources, the trials to be conducted include exploration of new combinations of compounds for the treatment of malaria in children and adults; evaluation of new generation, rapid acting treatment for severe malaria that is majorly being developed by Novartis; and testing of formulation of existing gold standard treatment artemether-lumefantrine in infants weighing less than 5kg.

Speaking on these trials, the Chief Scientific Officer of MMV and coordinator of PAMAfrica group, Dr. Timothy Wells commented that all the trials are estimated to address the areas of urgent need in the malaria treatment. The development on newborn and severe malaria is incredible in bringing treatments to this group. He further added that the support of EDCTP would not only bring together the necessary European and African clinical proficiency, but it would also support the training and development of next-gen leaders in clinical malaria research in the states of Africa.

Source credits: https://www.novartis.com/news/media-releases/international-research-partnership-and-edctp-invest-eu44m-next-generation-antimalarials-combat-drug-resistant-malaria-africa



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...